Abstract 13600: LDL Levels and Lipid Lowering Management Across Age Groups in Mexican Population. Analysis From the Mexican Registry of Cardiovascular Diseases (REMECAR)

• Published in: Circulation (New York, N.Y.) N.Y.), 2023-11, Vol.148 (Suppl_1)
• Main Authors: De Los Rios, Manuel O, Leiva-Pons, Jose L, Alcocer Gamba, Marco A, Cortes Lawrenz, Jorge, Alejandro, Ricalde, Virgen-Carrillo, Luis R, Pavia-Lopez, Abel A, Lugo-Gavidia, Leslie M
• Format: Article
• Language: English
• ISSN: 0009-7322; 1524-4539
• DOI: 10.1161/circ.148.suppl_1.13600

Abstract only Background and Aims: Age is a major determinant of cardiovascular (CV) risk. While younger people are more likely to have lower CV risk they may have other risk factors that can impact the long-term development of cardiovascular disease. Among them, dyslipidemia has a crucial role in the development of atherosclerotic disease (ASCVD). Objective: This analysis aimed to compare LDL levels and lipid lowering management in patients with dyslipidemia across different age groups Methods: The REMECAR registry is a prospective, multicentre, observational study of patients attending to outpatient cardiovascular clinics for diagnostic, and clinical management of cardiometabolic diseases. Patients were classified according to their age group. Results: A total of 6,138 patients with a previous diagnosis of dyslipidemia were included in the analysis. The prevalence of ASCVD and comorbidities progressively increased with older age, while younger patients presented higher proportions of modifiable risk factors (Alcohol consumption, Smoking). Younger patients had significantly higher cholesterol, LDL-c, and triglycerides levels compared with groups >60 years (Figure 1A). Most of the patients 190mg/dL (6.3%) and with triglycerides>500mg/dL (4.8%). Low/Moderate Statin was the most frequent treatment, high-intensity statins were used in less than 20% of all groups despite the increasing prevalence of ASCVD (Figure 1B). Conclusions: A stepwise therapy escalation is reasonable in young patients, as the risk of CV events is not immediately perceived. However, this also prolongs long-term exposure if proper management is not established on time, leading to the progression of the disease. Our results underline the urgent need to improve population awareness, proper follow-up, and optimization of lipid-lowering management.